USP <788> dictates the required particle thresholds and testing procedures for subvisible particulate matter in injectable pharmaceutical products. The August 2026 update renames the chapter, broadens its application to IM and SC administration routes, and achieves complete global pharmacopeial alignment with the EP and JP.
Understanding the relationship between USP <788> and its supplementary guide, USP <1788>, is crucial for establishing a thorough, inspection-ready quality control program.
What is USP <788>?
USP <788>, officially titled ‘Subvisible Particulate Matter in Injections’ as of August 2026, is a compulsory general chapter from the United States Pharmacopeia. It establishes numerical thresholds and testing methodologies for particulate matter in injectable drug formulations.
As it is in the first 1000 chapters, it is considered compendial, making compliance obligatory for products circulating in the US market.
In this context, particulate matter refers to mobile, undissolved extraneous particles within injectable solutions, specifically excluding gaseous bubbles. These particles typically range from about 2 µm to several hundred micrometers and can originate from the active drug substance, the manufacturing environment, the container-closure system, or components of delivery devices.
Given that injectable products are introduced directly into the bloodstream or tissues, even minute particles pose patient safety concerns, including capillary obstruction, inflammatory reactions, and immunogenicity, especially in biologic therapies.
USP <788> defines the foundational requirements for particle control. Understanding its limits, procedures, and scope forms the bedrock of any injectable quality control program.
A Key Distinction: Subvisible Versus Visible Particles
USP <788> governs particles too small for reliable visual detection, generally ranging from 2–100 µm; visible particles are addressed separately by USP <790>. A complete particle control strategy encompasses both particle size ranges. Subvisible particles are a significant concern for biologics because protein aggregates in this size range can elicit immune responses that larger, visible particles do not.
How USP <788> Connects to Other Chapters
USP <788> is part of a larger system of compendial and informational chapters that address particulate matter across various product categories. Identifying mandatory versus informational chapters is the initial step for any compliance initiative.
788: Subvisible Particulate Matter in Injections - Mandatory: This principal chapter outlines numerical limits and testing methods for the majority of parenteral products.
787: Subvisible Particulate Matter in Therapeutic Protein Injections - Mandatory: This applies the USP <788> framework specifically to therapeutic protein formulations (biotherapeutics, mAbs, gene therapies). It uses the same LO/MPC methodology, with additional guidance tailored to protein aggregation and sample handling.
789: Particulate Matter in Ophthalmic Solutions - Mandatory: This chapter pertains to ophthalmic drug products. Products intended for ocular administration are exempt from USP <788> but must adhere to USP <789>, which sets more rigorous limits to account for the sensitivity of ocular tissues.
790: Visible Particulates in Injections - Mandatory: This chapter regulates particles detectable by visual inspection (typically > 100 µm). It complements USP <788> to ensure coverage across the entire particle-size spectrum relevant to injectable safety.
1788: Methods for Determination of Subvisible Particulate Matter - Informational: This serves as the practical guide to USP <788>. It elaborates on the correct execution of LO and MPC techniques, the situations where complementary methods such as flow imaging/DIA are beneficial, best practices for sample management, and system suitability checks. While not independently enforceable, it is increasingly referenced in FDA 483 observations.
1787: Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections - Informational: This informational companion to USP <787> offers direction on supplementary analytical methods and risk assessment for protein aggregate characterization programs.
The Practical Structure
USP <788> specifies the required limits and permissible testing methods. USP <1788> provides instruction on how to execute these methods correctly and when supplemental data offers added value. Compendial chapters establish the baseline; informational chapters define optimal practices that go beyond this foundation.
Who Is Obligated to Comply with USP <788>?
USP <788> applies to manufacturers producing injectable drug products for the US market. The August 2026 revision has clarified and expanded its reach in several key areas.
IV Products (LVP and SVP): Large- (≥ 100 mL) and small-volume parenterals (< 100 mL) administered intravenously are fundamental to the scope of USP <788>.
IM and Subcutaneous (2026): The August 2026 revision explicitly extends requirements to IM and SC routes, resolving prior regulatory uncertainties for these product classifications.
Biotherapeutics: Protein-based biologics, mAbs, and cell/gene therapies are subject to the requirements of both USP <787> and USP <788>.
Combination Products: Drug-device systems (such as prefilled syringes and autoinjectors) must address particulate contributions from both the drug formulation and the device components, including silicone oil used for barrel lubrication.
Exemptions Under USP 788
Source: Vision Analytical Inc.
| Product Category |
Status |
Notes |
| Ophthalmic solutions |
Exempt →
USP 789 |
Must comply with USP <789> instead |
| Irrigating solutions |
Exempt |
Packaged/labeled exclusively for irrigation use |
| Radiopharmaceuticals |
Exempt |
Radiopharmaceutical preparations are explicitly excluded |
Products requiring
final filtration |
Conditional |
Exemption requires documented scientific justification (2026 revision tightened this) |
Veterinary
IM/SC products |
Indefinitely
postponed |
The 2026 IM/SC scope expansion is postponed for veterinary use |
USP <788> Particle Thresholds
USP <788> sets numerical limits at two particle size thresholds, ≥ 10 µm and ≥ 25 µm, with distinct limits for large- and small-volume parenterals. These thresholds remain unchanged in the 2026 revision.
Source: Vision Analytical Inc.
| Product Type |
Definition |
≥ 10 µm Limit |
≥ 25 µm Limit |
Method |
| Large-Volume Parenterals (LVP) |
≥ 100 mL per container |
≤ 25 particles/mL |
≤ 3 particles/mL |
Light obscuration
(primary) |
| Small-Volume Parenterals (SVP) |
< 100 mL per container |
≤ 6000 particles/
container |
≤ 600 particles/container |
Light obscuration
(primary) |
| SVP: Microscopy Fallback |
< 100 mL per container |
≤ 3000 particles/
container |
≤ 300 particles/
container |
Membrane particle count (MPC) |
Reason for Stricter Microscopy Limits
The more stringent numerical limits for MPC are attributed to its lower sensitivity compared to LO. A reduced pass threshold is implemented to maintain equivalent patient protection.
LO and MPC are alternative methods; if a product meets the LO criteria, it is not necessary to also meet the MPC limits. Documentation should clearly state the chosen method and the rationale behind it.
For therapeutic protein injections (USP <787>), the same ≥ 10 µm and ≥ 25 µm thresholds are applicable. USP <787> additionally provides protein-specific guidance on sample dilution requirements and the management of intrinsic protein aggregates that could affect LO measurements.
This information has been sourced, reviewed, and adapted from materials provided by Vision Analytical Inc.
For more information on this source, please visit Vision Analytical Inc.